These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 37357964)

  • 1. Impact of Supplementary Immunization Activities using Novel Oral Polio Vaccine Type 2 during a Large outbreak of Circulating Vaccine-Derived Poliovirus in Nigeria.
    Voorman A; Lyons H; Shuaib F; Adamu US; Korir C; Erbeto T; Bandyopadhyay AS; Okiror S
    J Infect Dis; 2024 Mar; 229(3):805-812. PubMed ID: 37357964
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of poliovirus vaccines against circulating vaccine-derived type 2 poliomyelitis in Nigeria between 2017 and 2022: a case-control study.
    Cooper LV; Erbeto TB; Danzomo AA; Abdullahi HW; Boateng K; Adamu US; Shuaib F; Modjirom N; Gray EJ; Bandyopadhyay AS; Zipursky S; Okiror SO; Grassly NC; Blake IM
    Lancet Infect Dis; 2024 Apr; 24(4):427-436. PubMed ID: 38246190
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk factors for the spread of vaccine-derived type 2 polioviruses after global withdrawal of trivalent oral poliovirus vaccine and the effects of outbreak responses with monovalent vaccine: a retrospective analysis of surveillance data for 51 countries in Africa.
    Cooper LV; Bandyopadhyay AS; Gumede N; Mach O; Mkanda P; Ndoutabé M; Okiror SO; Ramirez-Gonzalez A; Touray K; Wanyoike S; Grassly NC; Blake IM
    Lancet Infect Dis; 2022 Feb; 22(2):284-294. PubMed ID: 34648733
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Implementing a robust adverse event of special interest surveillance for novel oral polio vaccine type 2 rollout, Nigeria, March-July 2021.
    Abbott SL; Etapelong SG; Gidado S; Mawashi KY; Edukugho AA; Hamisu AW; Shehu A; Adedire E; Hassan IA; Waziri NE; Bolu O; Adamu US
    Pan Afr Med J; 2023; 45(Suppl 2):6. PubMed ID: 38370101
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Update on Vaccine-Derived Poliovirus Outbreaks - Worldwide, July 2019-February 2020.
    Alleman MM; Jorba J; Greene SA; Diop OM; Iber J; Tallis G; Goel A; Wiesen E; Wassilak SGF; Burns CC
    MMWR Morb Mortal Wkly Rep; 2020 Apr; 69(16):489-495. PubMed ID: 32324719
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vaccine-derived poliovirus serotype 2 outbreaks and response in the Democratic Republic of the Congo, 2017-2021.
    Alleman MM; Jorba J; Riziki Y; Henderson E; Mwehu A; Seakamela L; Howard W; Kadiobo Mbule A; Nsamba RN; Djawe K; Yapi MD; Mengouo MN; Gumede N; Ndoutabe M; Kfutwah AKW; Senouci K; Burns CC
    Vaccine; 2023 Apr; 41 Suppl 1(Suppl 1):A35-A47. PubMed ID: 36907733
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serotype 2 oral poliovirus vaccine (OPV2) choices and the consequences of delaying outbreak response.
    Kalkowska DA; Pallansch MA; Wassilak SGF; Cochi SL; Thompson KM
    Vaccine; 2023 Apr; 41 Suppl 1(Suppl 1):A136-A141. PubMed ID: 33994237
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Updated Characterization of Outbreak Response Strategies for 2019-2029: Impacts of Using a Novel Type 2 Oral Poliovirus Vaccine Strain.
    Kalkowska DA; Pallansch MA; Wilkinson A; Bandyopadhyay AS; Konopka-Anstadt JL; Burns CC; Oberste MS; Wassilak SGF; Badizadegan K; Thompson KM
    Risk Anal; 2021 Feb; 41(2):329-348. PubMed ID: 33174263
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Deployment of novel oral polio vaccine type 2 under emergency use listing in Nigeria: the rollout experience.
    Asekun A; Nkwogu L; Bawa S; Usman S; Edukugho A; Ocheh J; Banda R; Nganda GW; Nsubuga P; Archer R; Nebechukwu T; Mohammed A; Shuaib F; Bolu O; Adamu U
    Pan Afr Med J; 2023; 45(Suppl 2):3. PubMed ID: 38370105
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Update on Vaccine-Derived Poliovirus Outbreaks - Worldwide, January 2020-June 2021.
    Alleman MM; Jorba J; Henderson E; Diop OM; Shaukat S; Traoré MA; Wiesen E; Wassilak SGF; Burns CC
    MMWR Morb Mortal Wkly Rep; 2021 Dec; 70(49):1691-1699. PubMed ID: 34882653
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exploring public perceptions of vaccine-derived poliovirus and a novel oral polio vaccine in the Democratic Republic of the Congo, Kenya, and Nigeria.
    Lorenzetti L; Haydarov R; Namey E; Lawton A; Nam H; Ridwan Hasan M; Monj C; Abeyesekera S; Amina Kabwau M; McIntosh R
    Vaccine; 2023 Apr; 41 Suppl 1():A128-A135. PubMed ID: 35871107
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modeling the spread of circulating vaccine-derived poliovirus type 2 outbreaks and interventions: A case study of Nigeria.
    Sun Y; Keskinocak P; Steimle LN; Kovacs SD; Wassilak SG
    Vaccine X; 2024 Jun; 18():100476. PubMed ID: 38617838
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of vaccine derived poliovirus type 2 outbreak response options: A randomized controlled trial, Karachi, Pakistan.
    Saleem AF; Yousafzai MT; Mach O; Khan A; Quadri F; Weldon WC; Oberste MS; Zaidi SS; Alam MM; Sutter RW; Zaidi AKM
    Vaccine; 2018 Mar; 36(13):1766-1771. PubMed ID: 29477307
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outbreak response strategies with type 2-containing oral poliovirus vaccines.
    Kalkowska DA; Wassilak SGF; Pallansch MA; Burns CC; Wiesen E; Durry E; Badizadegan K; Thompson KM
    Vaccine; 2023 Apr; 41 Suppl 1(Suppl 1):A142-A152. PubMed ID: 36402659
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Implementation of coordinated global serotype 2 oral poliovirus vaccine cessation: risks of inadvertent trivalent oral poliovirus vaccine use.
    Duintjer Tebbens RJ; Hampton LM; Thompson KM
    BMC Infect Dis; 2016 Jun; 16():237. PubMed ID: 27246198
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of serological responses following vaccination campaigns with type 2 novel oral polio vaccine: a population-based study in Tajikistan in 2021.
    Mirzoev A; Macklin GR; Zhang Y; Mainou BA; Sadykova U; Olsavszky VS; Huseynov S; Ruziev M; Saidzoda F; Bobokhonova M; Mach O
    Lancet Glob Health; 2022 Dec; 10(12):e1807-e1814. PubMed ID: 36400086
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Strategic Response to an Outbreak of Circulating Vaccine-Derived Poliovirus Type 2 - Syria, 2017-2018.
    Mbaeyi C; Wadood ZM; Moran T; ; Ather F; Stehling-Ariza T; Nikulin J; Al Safadi M; Iber J; Zomahoun L; Abourshaid N; Pang H; Collins N; Asghar H; Butt OUI; Burns CC; Ehrhardt D; Sharaf M
    MMWR Morb Mortal Wkly Rep; 2018 Jun; 67(24):690-694. PubMed ID: 29927908
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Looking back at prospective modeling of outbreak response strategies for managing global type 2 oral poliovirus vaccine (OPV2) cessation.
    Thompson KM; Kalkowska DA; Badizadegan K
    Front Public Health; 2023; 11():1098419. PubMed ID: 37033033
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic Characterization of Novel Oral Polio Vaccine Type 2 Viruses During Initial Use Phase Under Emergency Use Listing - Worldwide, March-October 2021.
    Martin J; Burns CC; Jorba J; Shulman LM; Macadam A; Klapsa D; Majumdar M; Bullows J; Frolov A; Mate R; Bujaki E; Castro CJ; Bullard K; Konz J; Hawes K; Gauld J; Blake IM; Mercer LD; Kurji F; Voorman A; Diop OM; Oberste MS; Modlin J; Macklin G; Eisenhawer M; Bandyopadhyay AS; Zipursky S
    MMWR Morb Mortal Wkly Rep; 2022 Jun; 71(24):786-790. PubMed ID: 35709073
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monovalent type 2 OPV (mOPV2) management in the field: Interventions and lessons learned.
    Afsar A; Mallya A; Mohammed AAG; Anand S; Diomande VKF; Maufras du Châtellier G; Ather F
    Vaccine; 2023 Apr; 41 Suppl 1():A79-A84. PubMed ID: 36642630
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.